Previous 10 | Next 10 |
Equillium (NASDAQ:EQ): Q3 GAAP EPS of -$0.35 misses by $0.01. Revenue of $0M Press Release Cash, cash equivalents and short-term investments totaled $90.7 million as of September 30, 2021. For further details see: Equillium EPS misses by $0.01
Announced plans to initiate a pivotal study of itolizumab in first-line treatment of acute graft-versus-host disease Reported decrease in proteinuria observed in subgroup of patients with lupus following two doses of itolizumab Reported interim safety data from first c...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in fireside chat presentations at the Stifel 2021 Virtual Healthcare Co...
Sustained decrease in proteinuria observed in subgroup of patients with systemic lupus erythematosus, without lupus nephritis, following two doses of itolizumab Dose dependent decreases in inflammatory marker CD6 following itolizumab administration Equillium, Inc. (N...
Itolizumab was well tolerated in patients with moderate to severe uncontrolled asthma Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today reported...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that two abstracts were accepted for presentation at the 63 rd annual meeting of the America...
Subgroup analyses of lupus patients (without lupus nephritis) that had elevated baseline proteinuria and albuminuria shows reduction of 42% and 54%, respectively, by Day 57 Itolizumab was well tolerated at doses ranging from 0.4 to 2.4 mg/kg Equillium, Inc. (Nasdaq: ...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that two abstracts were accepted for presentation at the virtual 2021 American Society of Nephro...
Equillium is a clinical-stage biotech company treating severe autoimmune and inflammatory disorders. CEO Bruce Steel discusses primary drug itolizumab pivotal study. Alternative to short-term, high dose steroid therapies. For further details see: Equillium CEO Bruce Stee...
News, Short Squeeze, Breakout and More Instantly...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will be participating in the Leerink Partners Therapeutic Forum: I&I and Metabolism, as well as the Jone...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effe...
A look at the top 10 most actives in the United States SOBR Safe Inc. (SOBR) rose 74.6% to $0.46 on volume of 265,324,361 shares MicroAlgo Inc. (MLGO) rose 669.9% to $12.01 on volume of 183,977,846 shares PROSHARES TRUST (SQQQ) fell 0.7% to $9.86 on volume of 124,114,596 shares Faraday ...